The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial.
 
Ana Elisa Lohmann
Honoraria - AstraZeneca; Gilead Sciences; La Roche Posay; Novartis; Pfizer
Research Funding - Epic Sciences (Inst); Merck (Inst)
Other Relationship - AstraZeneca (Inst); Gilead Sciences (Inst); Knight Therapeutics (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Bingshu Chen
No Relationships to Disclose
 
Wendy Parulekar
No Relationships to Disclose
 
Katarzyna Jerzak
Honoraria - Amgen; Apobiologix; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Exact Sciences; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Merck; Myriad Genetics; Novartis; Pfizer; Roche; Seagen; Viatris
Consulting or Advisory Role - Amgen; Apobiologix; AstraZeneca; Daiichy Sankyo; Eisai; Genomic Health; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Myriad Genetics; Novartis; Pfizer; Roche; Seagen; Viatris
Research Funding - AstraZeneca; Lilly; Seagen
Patents, Royalties, Other Intellectual Property - I am the lead inventor on a patent for the use of dronedarone and its structural derivatives as cancer therapies.
Travel, Accommodations, Expenses - Agendia; AstraZeneca/Daiichi Sankyo
Other Relationship - Viatris
 
Pamela Goodwin
No Relationships to Disclose